Pharmacokinetics and pharmacodynamics of famotidine in paediatric patients

Clinical Pharmacokinetics

Volumn 31, Issue 2, 1996, Pages 103-110

  James, Laura P ^a   Kearns, Gregory L ^b  

^a ARKANSAS CHILDREN S HOSPITAL   (United States)

^b CHILDREN S MERCY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CIMETIDINE; CYTOCHROME P450; FAMOTIDINE; HISTAMINE H2 RECEPTOR ANTAGONIST; RANITIDINE;

ADOLESCENT; CHILD; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; ESOPHAGITIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY DISEASE; META ANALYSIS; ORAL DRUG ADMINISTRATION; PEDIATRICS; PEPTIC ULCER; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; REVIEW;

EID: 0029901201     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-199631020-00002     Document Type: Review

References (21)

1. Echizen H, Ishizaki T. Clinical pharmacokinetics of famotidine. Clin Pharmacokinet 1991; 21 (3): 178-94
2. Kraus G, Krishna DR, Chmelarsch D, et al. Famotidine: pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery. Clin Pharmacokinet 1990; 18 (1): 77-81
3. Nagita A, Manago M, Aoki S, et al. Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers. Ther Drug Monit 1994; 16: 444-9
4. James LP, Marshall JD, Heulitt MJ, et al. Pharmacokinetics and pharmacodynamics of famotidine in children. J Clin Pharmacol 1996; 36: 48-54
5. 2-receptor antagonists: clinical pharmacokinetics and drug interaction potential. Clin Pharmacokinet 1988; 15: 205-15
6. Echizen H, Shoda R, Umeda N, et al. Plasma famotidine concentration versus intragastric pH in patients with upper gastrointestinal bleeding and in healthy subjects. Clin Pharmacol Ther 1988; 44: 690-8
7. Kroemer H, Klotz U. Pharmacokinetics of famotidine in man. Int J Clin Pharmacol Ther Toxicol 1987; 25: 458-63
8. Yeh KC, Chremos AN, Lin JH, et al. Single-dose pharmacokinetics and bioavailability of famotidine in man: results of multicenter collaborative studies. Biopharm Drug Dispos 1987; 8: 549-60
9. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin Pharmacokinet 1981; 6: 429-53
10. Treem WR, Davis PM, Hyams JS. Suppression of gastric acid secretion by intravenous administration of famotidine in children. J Pediatr 1991; 118 (5): 812-6
11. West JR, Smith HW, Chasis H. Glomerular filtration rate, effective renal blood flow and maximal tubular-excretory capacity in infancy. J Pediatr 1948; 32: 10-8
12. Guignard JP. Glomerular filtration rate in the first three weeks of life. J Pediatr 1975; 87: 236-75
13. Kearns GL, Reed MD. Clinical pharmacokinetics in infants and children: a reappraisal. Clin Pharmacokinet 1989; 17 Suppl. 1: 29-67
14. 2 receptor antagonists have a therapeutic role in childhood? J Pediatr Gastroenterol Nutr 1994; 19: 270-6
15. 2-receptor antagonist, in relation to renal function. Eur J Clin Pharmacol 1985; 28: 327-31
16. Lin JH, Chremos AN, Yeh KC, et al. Effects of age and chronic renal failure on the urinary excretion kinetics of famotidine in man. Eur J Clin Pharmacol 1988; 34: 41-6
17. Behrens R, Hofbeck M, Singer H, et al. Frequency of stress lesions of the upper gastrointestinal tract in paediatric patients after cardiac surgery: effects of prophylaxis. Br Heart J 1994; 72: 186-9
18. Jahr JS, Burckart G, Smith SS, et al. Effects of famotidine on gastric pH and residual volume in paediatric surgery. Acta Anaesthesiol Stand 1991; 35: 457-60
19. 2-blocker, famotidine, in reflux esophagitis among severely handicapped children. Clin Ther 1987; 9 (5): 548-58
20. Carroccio A, Pardo F, Montalto G, et al. Use of famotidine in severe exocrine pancreatic insufficiency with persistent maldigestion on enzymatic replacement therapy: a long-term study in cystic fibrosis. Dig Dis Sci 1992; 37 (9): 1441-6
21. Chalmers DM, Brown RC, Miller MD, et al. The influence of long-term cimetidine as an adjuvant to pancreatic enzyme therapy in cystic fibrosis. Acta Paediatr Scand 1985; 74: 114-7